SCYX-2035811
objective
Progress a backup nitroimidazole into pre-clinical development
project start
Jun 2011
project status
Completed
last phase of drug development

Drug Discovery

Translational research

Clinical trials

Registration & access
The nitroimidazole backup programme for HAT identified SCYX-2035811 as a suitable candidate for further exploration, and although initial results in animal models had shown excellent activity, further studies showed the doses tested to give insufficient cure. Given the progress of fexinidazole (Phase II/ III) and SCYX-7158 (Phase I), further development was put on hold in 2013, and the project has now been stopped.
- Auckland University, New Zealand
- Pace University, USA
- SCYNEXIS Inc, USA
- TB Alliance, USA
- WuXi AppTech, China
- Germany - Federal Ministry of Education and Research (BMBF) through KfW
- Spain - Spanish Agency for International Development Cooperation (AECID)
- Switzerland - Swiss Agency for Development and Cooperation (SDC)
- The Netherlands - Dutch Ministry of Foreign Affairs (DGIS)
- UK - UK International Development
- Médecins Sans Frontières International
- Other private foundations and individuals
Stay connected
Get our latest news, personal stories, research articles, and job opportunities.